This is an exciting time for chronic lymphocytic leukemia (CLL) research, with the possibility of chemotherapy-free treatment approaches. In this interview, Florence Cymbalista, MD, of Avicenne Hospital, Bobigny, France, discusses the Phase II study of obinutuzumab plus ibrutinib, followed by a chemo-sparing strategy, in treatment-naïve CLL patients (ICLL07GAI; NCT02666898). The preliminary results are encouraging, with the full dataset highlight anticipated at next year’s meeting. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
A "chemo-sparing" MRD-driven strategy for CLL
